Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-807-0 | CAS number: 126-83-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 November 2016 - 11 July 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Sodium 3-chloro-2-hydroxypropanesulphonate
- EC Number:
- 204-807-0
- EC Name:
- Sodium 3-chloro-2-hydroxypropanesulphonate
- Cas Number:
- 126-83-0
- Molecular formula:
- C3H7ClO4S.Na
- IUPAC Name:
- sodium 3-chloro-2-hydroxypropanesulphonate
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD(SD)
- Details on species / strain selection:
- The Crl:CD(SD) rat is recognized as appropriate for reproductive toxicity studies and has been proven to be susceptible to the effects of reproductive toxicants. In addition, the testing laboratory has reproductive historical control data in the Crl:CD(SD) rat.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC.
- Age at study initiation: Approximately 10 weeks.
- Weight at study initiation: 307-394 gr (males) or 201-291 gr (females)
- Fasting period before study: no. All males and females (including those not selected for clinical pathology evaluation) were fasted prior to clinical pathology blood collection when food, but not water, was withheld.
- Housing:
Pre-mating: Animals were housed in groups of 2-3 animals/sex/cage in solid-bottom cages.
Mating: Females were caged together with males on a one-to-one-basis.
Post-mating: Males and females were individually housed until the schedule necropsy.
General: Sterilised sawdust as bedding material and paper as cage enrichment were supplied.
- Diet: Free access to pelleted rodent diet (PMI Nutrition International, LLC Certified Rodent LabDiet® 5002), except o/n before sacrifice.
- Water: Free access to tap water.
- Acclimation period: 20 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 26 (actual range during study 21.8 - 23.1)
- Humidity (%): 30 - 70 (actual range during study 33.0 - 44.2)
- Air changes (per hr): at least 10
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 29 November 2016 to 20 February 2017
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The selected route of administration for this study was oral (gavage) because this is a potential route of exposure for humans. Historically, this route has been used extensively for studies of this nature.
The vehicle and test substance formulations were administered via appropriately sized, flexible, disposable, plastic feeding tubes - Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The vehicle suspension was prepared approximately weekly for administration to the control group and for preparation of the test substance formulations. Following formulation, the pH of the vehicle was adjusted to a pH of 3.5 ± 0.4 using 2 N or 5 N HCl. Aliquots were prepared for daily dispensation to the control group and stored refrigerated (2°C to 8°C). The vehicle was mixed throughout the preparation, sampling, and dose administration procedures.
The test substance formulations were prepared approximately weekly as single formulations for each dosage level, divided into aliquots for daily dispensation, and stored refrigerated (2°C to 8°C). The test substance formulations were stirred continuously throughout the preparation, sampling, and dose administration procedures.
VEHICLE: 0.5% carboxymethylcellulose (CMC) and 0.1% Tween® 80 in deionized water, pH 3.5
- Justification for use and choice of vehicle (if other than water): Vehicle is accepted in international guidelines and use of vehicle resulted in formulations acceptable for administration.
- Concentration in vehicle: 25, 50 and 100 mg/mL
- Amount of vehicle (if gavage): 10 mL. Actual dose volumes were calculated according to the latest body weight. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of dose preparations were collected at the test facility and analyzed for homogeneity (first 250 and 1000 mg/kg bw/day dosing formulations) and concentration (first, third and last dosing formulations of all dose groups including control). In addition, samples were analyzed for resuspension homogeneity and stability (the first 250 and 1000 mg/kg bw/day dosing suspensions following refrigerated (2°C to 8°C) storage for 10 days).
The accuracy of preparation was considered acceptable if the mean measured concentrations were 85-115% of the target concentration. Homogeneity was demonstrated if the relative standard deviation was ≤ 10%. Formulations were considered stable if the relative difference before and after storage was maximally 10%. - Duration of treatment / exposure:
- Males were exposed for 28 days, i.e. 2 weeks prior to mating, during mating, and up to termination. Females were exposed for 50-63 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation. Females with no evidence of mating were dosed for 52 days through the day prior to euthanasia (Postcohabitation Day 25).
- Frequency of treatment:
- Once daily, 7 d/w
Doses / concentrationsopen allclose all
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were based on results of a 10-Day dose range finding study. In this study, the test substance was administered to males and females at dosage levels of 100, 250 and 500 mg/kg/day. The test substance was well tolerated in both males and females, with no significant adverse effects at any dosage level. Therefore, a high-dosage level of 1000 mg/kg/day was used in the current study as the limit dose, which was expected to produce signs of toxicity, without causing mortality. Dosage levels of 250 and 500 mg/kg/day were selected as the low- and mid-dosage levels to establish a dose response and a no-observed-adverse-effect level (NOAEL).
Selection of animals for selected measurements:
5 animals/sex/group were randomly selected at allocation for functional observations, clinical pathology, macroscopic examination, organ weights and histopathology (see also respective paragraphs). Only females with live offspring were selected. - Positive control:
- No.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS:
Yes
- Time schedule: Twice daily.
DETAILED CLINICAL OBSERVATIONS:
Yes
- Time schedule: Individual clinical observations were recorded daily and detailed physical examinations were conducted weekly (prior to dose administration during the treatment period). Each male and female was also observed for signs of toxicity approximately 2 hours following dose administration.
BODY WEIGHT:
Yes
- Time schedule for examinations: Males and females were weighed on the first day of exposure and weekly thereafter. Mated females were weighed on days 0, 4, 7, 11, 14, 17 and 20 post-coitum, and during lactation on days 0 (when possible), 1, 7, 10, 13 and 14.
FOOD CONSUMPTION:
Yes. Weekly, for males and females. Food consumption was not recorded during the mating period. Food consumption of mated females was measured on days 0, 4, 7, 11, 14, 17 and 20 post-coitum and on days 1, 4, 7, 10 and 13 of lactation.
FOOD EFFICIENCY:
No.
WATER CONSUMPTION : No.
Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY:
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination.
- Anaesthetic used for blood collection: Blood was collected via the jugular vein using the hand-held restraint method for males and via the retro-orbital sinus following isoflurane anesthesia for females
- Animals fasted: Yes (with a maximum of 20 hours). Water was provided.
- How many animals: 5 animals/sex/group
- Parameters checked were: According to test guideline
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination.
- Animals fasted: Yes (overnight). Water was provided.
- How many animals: 5 animals/sex/group
- Parameters checked were: According to test guideline
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION:
Yes
- Time schedule for examinations: The selected males were tested during Week 4 of treatment and the selected females were tested during lactation (LD13) (all before blood sampling).
- Dose groups that were examined: all (5 animals/sex/group)
- Battery of functions tested: According to test guideline. Home cage observations, open field observations, sensory observations and neuromuscular observations were performed. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Animals surviving to scheduled necropsy and all moribund animals were deeply anaesthetised and subsequently exsanguinated.
- all F0 parental animals found dead, euthanized in extremis, or at the scheduled termination:
According to test guideline
- All remaining females which failed to deliver and the remaining males: According to test guidelines
ORGAN WEIGHTS
- All F0 animals: According to test guideline
HISTOPATHOLOGY: Yes
According to test guideline in 5 animals/sex/group in the control and 1000 mg/kg bw/day groups and in all animals dying spontaneously - Statistics:
- The following statistical methods were used to analyse the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (Dunnett, 1955) (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Fisher Exact-test (Fisher, 1950) was applied to frequency data.
Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing each test substance-treated group to the control group by sex.
Ambulatory and total counts measured during motor activity assessments were analyzed by sex and session, with a RMANOVA (SAS version 9.2). Factors in the model included treatment group (TRT), time interval (TIME), and the interaction of time interval and treatment group (TRT*TIME). The SAS® procedure PROC MIXED was used for analysis with the random effect of animal included as the repeated measurement. The covariance structure across time was selected by comparing Akaike’s Information Criterion (AIC).
The monotonic dose-response relationship was evaluated using sequential linear trend tests based on ordinal spacing of dosage levels. The linear dose by time interaction (LinTrt*Time) was evaluatedusing trend tests on treatment means were performed at the 0.05 level for each time interval or across the pooled time intervals by session only.
Nonmonotonic dose responses were evaluated whenever no significant linear trends were detected but TRT and/or TRT*TIME interaction was significant at the 0.01 level.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- All F0 males and females in the test substance-treated groups survived to the scheduled necropsies. In the control group, one F0 female was found dead on Gestation Day 12; no clinical observations or noteworthy changes in body weight were noted for this female prior to death. Following macroscopic and microscopic examinations, the cause of death was determined to be an acute pericardial hemorrhage. An additional F0 Female in the control group was euthanized in extremis on Lactation Day 0 due to poor clinical condition, including observations of a cool and pale body and extremities at the daily examinations on the day prior to and/or the day of euthanasia. Following macroscopic and microscopic examinations, the cause of the moribund condition of this female was uterine hemorrhage, which was consistent with uterine torsion noted at the gross examination. All other control group animals survived to the scheduled necropsies.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A significantly (p < 0.01) higher mean body weight gain was noted in F0 males in the 500 mg/kg/day group during Study Days 7–13 compared to the control group. However, this difference was transient and not of sufficient magnitude to affect the mean body weight gains during the pre-mating (Study Days 0–13) and entire treatment (Study Days 0–27) periods, or mean body weights at this dosage level, and did not occur in a dose-related manner. Therefore, the higher mean body weight gain noted in the 500 mg/kg/day group was not considered test substance-related.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- A significantly (p < 0.05) lower (15.5%) mean platelet count was noted for F0 males in the 1000 mg/kg/day group compared to the control group. In the absence of other noteworthy changes in hematology and coagulation parameters at this dosage level, the difference was considered to be the result of normal biological variation and of no toxicological significance.
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- During open field oberservations significantly (p < 0.05 or p < 0.01) longer mean times to first step (0.6 and 0.7 seconds) were noted for F0 females in the 250 and 500 mg/kg/day groups, respectively, compared to the control group (0.3 seconds). In the absence of a dose-related response, the differences were not considered test substance-related. In addition, the mean time to first step values in the 250 and 500 mg/kg/day groups were within the range of values (0.22 to 1.15 seconds) in the testing laboratory historical control data (version 2016.02).
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A significantly (p < 0.05) higher mean relative (to brain weight) left testis weight was noted in the 1000 mg/kg/day group F0 males compared to the control. No histologic correlates were detected to account for the higher mean testis weight. In addition, the mean absolute left testis and brain weights, and left testis to brain weight ratio were generally within the testing laboratory historical control data ranges. The higher mean left testis weight in the 1000 mg/kg/day group F0 males can be partially explained by the data showing that 1 control group male had a left testis weight approximately 26% lower than the mean for that group, and was lower (outside of mean ± 2 S.D.) compared to the testing laboratory historical control data. Therefore, the higher mean left testis weight relative to brain weight in the 1000 mg/kg/day group F0 males was not considered to be test substance-related.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no test substance-related effects on thyroid hormone values in the F0 males at any dosage level. The mean lengths of estrous cycles in F0 females at any dose level were comparable to the control.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Parental generation
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No toxicity was observed up to and including the highest dose level tested.
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Analytical verification of the test item concentrations
No test substance was detected in the analyzed vehicle administered to the control group.
The concentrations analysed in the first, third and last formulations of 250, 500 and 1000 mg/kg bw/day groups were in agreement with the target concentrations. Mean accuracies were 86.8%, 96.9% and 109% for the 250 mg/kg bw/day group (n = 6, 2 and 2, respectively), 88.3%, 95.4% and 109% for the 500 mg/kg bw/day group (n=2) and 88.4%, 99.7% and 108% for the 1000 m/kg bw/day group (n = 6, 2 and 2, respectively). The formulations of 250 and 1000 mg/kg bw/day groups were homogeneous (i.e. relative standard deviation 6.8% and 6.6%, respectively).
Formulations at the entire range were stable following 10 days of refrigerated storage (i.e. relative difference ≤ 10%).
Applicant's summary and conclusion
- Conclusions:
- In an oral OECD422 study with rats conducted in accordance with GLP principles, the NOAEL was determined to be 1000 mg/kg bw/day, based on the absence of adverse effects up to and including the highest dose level.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.